Ingrid Desar1, H. W.M. van Laarhoven1, T. Hambrock2, E. G.W. ter Voert2, J. J.A. van Asten2, D.J. van Spronsen3, J. O. Barentsz2, P. F.A. Mulders4, A. Heerschap2, Carla M.L. van Herpen1
1Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 2Radiology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 3Medical Oncology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands; 4Urology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Sunitinib is an oral angiogenesis inhibitor, used as first line treatment in patients with metastatic renal cell cancer (RCC). A successful antiangiogenic treatment is expected to result in stabilization of the vasculature, a reduction in permeability and in interstitial fluid pressure, and the development of necrosis. This study aims to assess the early vascular effects of sunitinib in RCC patients with a DCE-MRI and DWI at 3T. Treatment with sunitinib provokes significant increases in ADC after 3 days, with recurrence to baseline values at day 10. This is possibly due to the development of edema and necrosis. In this limited number of patients, no significant changes in both mean kep and Ktrans values, as well as in the histogram results were found, although in individual patients some trends indicative for early vascular effects of sunitinib were observed.